NASDAQ$NRIX
Nurix Therapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended February 28, 2021 and provided a corporate update.
Nurix Therapeutics reported collaboration revenue of $5.0 million for the first quarter of 2021, compared to $2.9 million for the same period in 2020. The net loss was $24.3 million, or ($0.63) per share. The company's cash, cash equivalents, and investments totaled $380.3 million as of February 28, 2021, and $530.4 million proforma including net proceeds from follow-on offering.
- Initiated first clinical trial to evaluate NX-2127, an orally available degrader of Bruton’s tyrosine kinase.
- On track to initiate Phase 1 trials for three more proprietary drug candidates in 2021.
- Expanded Sanofi collaboration resulting in option exercise payment of $22 million.
- Completed a public follow-on offering with net proceeds of approximately $150 million.
Headline financials
Revenue & EPS history
Nurix · Revenue · Quarterly
$5.01M
Revenue by segment
Nurix · $5.01M total across 1 segment · Q1 2021
- Collaboration revenue$5.01M—100.0%
Forward guidance
Nurix anticipates initiating Phase 1 trials for NX-1607, NX-5948 and DeTIL-0255 in the second half of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
+2.9%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.8%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+35.6%
Q1 2023
Best reaction
-13.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -4.2% | +4.5% | +5.9% | |
| Q4 2025 | -1.7% | -6.0% | -10.6% | |
| Q3 2025 | -10.1% | -4.7% | +13.4% | |
| Q2 2025 | -4.3% | -11.7% | -16.8% | |
| Q1 2025 | +7.8% | +12.0% | +4.8% | |
| Q4 2024 | +0.5% | -3.1% | -21.0% | |
| Q3 2024 | +15.1% | +18.1% | +25.1% | |
| Q2 2024 | +17.7% | +12.7% | +2.9% | |
| Q1 2024 | -1.5% | -11.6% | -22.7% | |
| Q4 2023 | +7.2% | +9.6% | +42.0% | |
| Q3 2023 | -3.9% | -8.3% | -20.5% | |
| Q2 2023 | -2.2% | -2.3% | -7.3% | |
| Q1 2023 | +35.6% | +29.9% | +14.8% | |
| Q4 2022 | +1.0% | -6.2% | -25.8% | |
| Q3 2022 | -13.2% | -12.6% | +2.5% | |
| Q2 2022 | +22.7% | +10.7% | +34.3% | |
| Q1 2022 | +7.2% | -3.7% | -30.8% | |
| Q4 2021 | -4.6% | +2.3% | -14.1% | |
| Q3 2021 | +0.1% | -1.6% | +18.3% | |
| Q2 2021 | -5.1% | +8.6% | +32.2% | |
| Q2 2020 | -5.1% | +8.6% | +32.2% | |
| Q1 2021 | +12.6% | +9.0% | -5.4% | |
| Q4 2020 | +3.0% | -4.2% | -1.3% | |
| Q3 2020 | -4.7% | +3.8% | +14.4% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro